The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction

W.F. Lems; J.P. van den Bergh; P.P.M.M. Geusens

doi:10.1007/s00198-022-06335-9

The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction

W.F. Lems^*, J.P. van den Bergh, P.P.M.M. Geusens

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	1639-1640
Number of pages	2
Journal	Osteoporosis International
Volume	33
Issue number	8
Early online date	15 Feb 2022
DOIs	https://doi.org/10.1007/s00198-022-06335-9
Publication status	Published - Aug 2022

Access to Document

10.1007/s00198-022-06335-9

Cite this

@article{5825aadae66e40a1b8445f254eac1872,

title = "The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction",

author = "W.F. Lems and {van den Bergh}, J.P. and P.P.M.M. Geusens",

note = "Funding Information: Prof Lems: speakers{\textquoteright} fee and advisory boards: Amgen, UCB, Eli Lilly, Pfizer, Galapagos. Prof van den Bergh: research funding from UCB and Amgen, consultant for UCB and Amgen. Prof Geusens: lectures and participation in clinical trials: Abbott, Amgen, BMS, Celgene, Janssen, Lilly, MSD, Merck, Novartis, Pfizer, Roche, UCB, Will-Pharma, Fresenius, Viatris, Sandoz, Galapagos. ",

year = "2022",

month = aug,

doi = "10.1007/s00198-022-06335-9",

language = "English",

volume = "33",

pages = "1639--1640",

journal = "Osteoporosis International",

issn = "0937-941X",

publisher = "Springer-Verlag London Ltd.",

number = "8",

}

TY - JOUR

T1 - The fracture liaison service, a step forward not only in fracture reduction, but also in mortality reduction

AU - Lems, W.F.

AU - van den Bergh, J.P.

AU - Geusens, P.P.M.M.

N1 - Funding Information: Prof Lems: speakers’ fee and advisory boards: Amgen, UCB, Eli Lilly, Pfizer, Galapagos. Prof van den Bergh: research funding from UCB and Amgen, consultant for UCB and Amgen. Prof Geusens: lectures and participation in clinical trials: Abbott, Amgen, BMS, Celgene, Janssen, Lilly, MSD, Merck, Novartis, Pfizer, Roche, UCB, Will-Pharma, Fresenius, Viatris, Sandoz, Galapagos.

PY - 2022/8

Y1 - 2022/8

U2 - 10.1007/s00198-022-06335-9

DO - 10.1007/s00198-022-06335-9

M3 - Editorial

C2 - 35166862

SN - 0937-941X

VL - 33

SP - 1639

EP - 1640

JO - Osteoporosis International

JF - Osteoporosis International

IS - 8

ER -